MedTrace Logo

Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

NCT03172936 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2022-05-03

No results posted yet for this study

Summary

The purpose of this study was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.

Conditions

  • Solid Tumors and Lymphomas

Interventions

DRUG

MIW815

MIW 815 (ADU-S100) is a STING agonist

BIOLOGICAL

PDR001

PDR001 is an anti-PD-1 antibody

Sponsors & Collaborators

Principal Investigators

  • Nancy Lewis, MD · Novartis

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-08
Primary Completion
2020-12-18
Completion
2020-12-18
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Germany
  • Japan
  • Netherlands
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03172936 on ClinicalTrials.gov